Literature DB >> 11577793

Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems.

L Kraut1, A A Fauser.   

Abstract

Currently, the most commonly used routes of administration of antiemetics in chemotherapeutic regimens are oral and intravenous. Patient compliance and thus efficacy of conventional drug schedules and formulations are often impaired by difficulties associated with oral or intravenous uptake of the administered chemotherapy. Alternative or new drug delivery systems should overcome these problems by improving patient compliance. Several new drug delivery systems are available and development of these new systems is ongoing, in particular to meet delivery requirements of modern biological therapeutics and the application of gene therapy. However, at the present time, the implementation of new techniques of alternative antiemetic drug administration for chemotherapy-induced emesis is very limited. The challenge for clinical investigations to further develop new delivery systems, in particular for antiemetic therapies, remains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577793     DOI: 10.2165/00003495-200161110-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  65 in total

1.  Comparison of buccal and oral prochlorperazine in the treatment of dizziness associated with nausea and/or vomiting.

Authors:  C M Bond
Journal:  Curr Med Res Opin       Date:  1998       Impact factor: 2.580

Review 2.  Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies.

Authors:  P L Andrews; R J Naylor; R A Joss
Journal:  Support Care Cancer       Date:  1998-05       Impact factor: 3.603

Review 3.  Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery.

Authors:  G Cevc
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1996       Impact factor: 4.889

4.  Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers.

Authors:  M L Citron; J R Reynolds; J Kalra; B G Kay; K A Nathan; N D Jaffe; F R Miller
Journal:  Cancer Treat Rep       Date:  1987-03

Review 5.  Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects.

Authors:  A Cave; P Arlett; E Lee
Journal:  Pharmacol Ther       Date:  1999-09       Impact factor: 12.310

6.  Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.

Authors:  R J Gralla; L B Tyson; L A Bordin; R A Clark; D P Kelsen; M G Kris; L B Kalman; S Groshen
Journal:  Cancer Treat Rep       Date:  1984-01

Review 7.  A new class of antiemetics: the NK-1 receptor antagonists.

Authors:  H Bleiberg
Journal:  Curr Opin Oncol       Date:  2000-07       Impact factor: 3.645

8.  Usefulness of liposomes as an intranasal dosage formulation for topical drug application.

Authors:  K Iwanaga; S Matsumoto; K Morimoto; M Kakemi; S Yamashita; T Kimura
Journal:  Biol Pharm Bull       Date:  2000-03       Impact factor: 2.233

Review 9.  Drug-delivery products and the Zydis fast-dissolving dosage form.

Authors:  H Seager
Journal:  J Pharm Pharmacol       Date:  1998-04       Impact factor: 3.765

10.  [Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting].

Authors:  W Tolksdorf; R Meisel; P Müller; H J Bender
Journal:  Anaesthesist       Date:  1985-12       Impact factor: 1.041

View more
  7 in total

1.  Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.

Authors:  Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland
Journal:  Oncologist       Date:  2019-12-04

2.  Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.

Authors:  Young Mi Seol; Hyo Jeong Kim; Young Jin Choi; Eun Mi Lee; Yang Soo Kim; Sung Yong Oh; Su Jin Koh; Jin Ho Baek; Won Sik Lee; Young Don Joo; Hyun Gi Lee; Eun Young Yun; Joo Seop Chung
Journal:  Support Care Cancer       Date:  2015-08-12       Impact factor: 3.603

3.  Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.

Authors:  Ralph V Boccia; Lucio N Gordan; Gemma Clark; Julian D Howell; Steven M Grunberg
Journal:  Support Care Cancer       Date:  2010-09-12       Impact factor: 3.603

Review 4.  Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.

Authors:  Rudolph M Navari; Lee S Schwartzberg
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

5.  Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.

Authors:  Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland
Journal:  Oncologist       Date:  2019-12-08

6.  Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management.

Authors:  Jay W Mason; Thomas E Moon
Journal:  Cancer Manag Res       Date:  2013-07-29       Impact factor: 3.989

Review 7.  Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.

Authors:  James Gilmore; Steven D'Amato; Niesha Griffith; Lee Schwartzberg
Journal:  Cancer Manag Res       Date:  2018-07-03       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.